Guselkumab for checkpoint inhibitor–exacerbated psoriasis in a patient with metastatic melanoma

Clicks: 13
ID: 319751
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #226 of 245 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 245 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Severe pembrolizumab-exacerbated psoriasis in a patient with disseminated stage IV melanoma posed a significant therapeutic challenge. Guselkumab resulted in rapid clinical improvement (PASI 12.3 to 3.1; DLQI 21 to 3), allowing pembrolizumab rechallenge without recurrence of severe psoriasis. This case highlights the potential role of IL-23 inhibition in immune checkpoint inhibitor-induced psoriasis while emphasising uncertainty surrounding oncological outcomes in this setting.
Reference Key
openalex_W7167480916 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag280
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.